Tesofensine
Inhibits the reuptake of Serotonin, Noradrenaline and Dopamine in the striatum and hypothalamus. Increases satiety and basal energy expenditure simultaneously.
- Massive weight loss (comparable to GLP-1)
- Increased energy and focus
- Total appetite suppression
- Antidepressant effect (potential)Massive weight loss (comparable to GLP-1)
- Antidepressant effect (potential)
- Severe insomnia.
- Increased heart rate/blood pressure.
- Dry mouth/Obstipation.Severe insomnia.
- Dry mouth/Obstipation.
Tesofensine is a triple monoamine reuptake inhibitor (dopamine, serotonin and noradrenaline) originally developed for Parkinson's, but which has shown unprecedented efficacy in suppressing appetite.
READ MORE
What it is (in plain language)
- It's not a peptide, but a molecule that acts on the brain to 'kill' hunger in three different ways. It keeps you satisfied, increases your focus and mood, and slightly raises your metabolism. It is considered one of the most powerful oral weight loss tools under investigation.
Why do you appear online so much
- It is described as the 'smart drug' for weight loss. Those who use it report an almost total loss of appetite without the anxiety typical of old stimulants, and it is seen as an alternative or complement to GLP-1 injectables.
How it is framed today (pragmatic view)
- 1) Evidence: Phase II results show weight loss superior to any current oral medication. 2) Objective: Control obesity and reduce hedonic appetite. 3) Risk: May increase heart rate; requires caution in people with a cardiovascular history.
How to use this form
- Read about the impact on neurotransmitters to understand the secondary cognitive benefits.
- Quick profile (curated by Subject 157)
- Class: Metabolic
- Status: Verified
- Use case: Fat Loss
- Route: Oral
- Tags: Oral|Fat Loss|Appetite
- Half-life: ~9 Days
- Start: Days
- Duration: Sustained
- Mechanism (high level)
Inhibits the reuptake of Serotonin, Noradrenaline and Dopamine in the striatum and hypothalamus. Increases satiety and basal energy expenditure simultaneously.
- Evidence (what the literature covers)
RESEARCH RANGE (Phase 3, Non-prescriptive):
Saniona (Denmark).
Level of Evidence: A.
- Safety and harm-reduction (non-prescriptive)
Risks: Severe insomnia.
Increased heart rate/blood pressure.
Dry mouth/Obstipation.
Interactions: MAOIs, SSRIs (risk of serotonergic syndrome).
- References (anchors)
- Astrup, A. (2008) - Tesofensine efficacy in obesity - https://doi.org/10.1016/S0140-6736(08)61525-1
- PubMed:19059048
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
